3 Japanese Stocks Trading Below Estimated Fair Value on Cash Flow Models

With global growth signals stabilizing, inflation trends mixed, and central banks weighing growth against price pressures, many investors are turning back to the basics of cash generation and valuation. The Undervalued Stocks Based On Cash Flows screener focuses on companies where discounted cash flow estimates from SWS suggest a gap between market price and fair value, highlighting potential mispricing. In this article, you will see three stocks from that screener that stand out on cash flow grounds, along with a clear breakdown of why they might appeal to value oriented investors watching today’s macro headlines.

Chugai Pharmaceutical (TSE:4519)

Overview: Chugai Pharmaceutical is a Japan based drug company focused on researching, developing, manufacturing, and selling advanced treatments in areas such as oncology, autoimmune disease, rare blood disorders, and infectious disease, including a wide range of monoclonal antibody and biologic therapies sold globally through its relationship with Roche.

Operations: Chugai generates all of its ¥1,291,229 million revenue from pharmaceuticals, with reporting by region that includes Japan at ¥482,036 million and Switzerland at ¥771,217 million.

Market Cap: ¥11.9t

Chugai Pharmaceutical catches attention because it blends a focused biologics portfolio with reported profitability metrics such as a net margin around 35% and return on equity close to 24%. Simply Wall St’s cash flow model suggests the shares trade below its estimated fair value. The pipeline in oncology and immunology, supported by Roche’s global distribution, feeds analyst expectations for double digit annual earnings growth. At the same time, reliance on a few blockbuster therapies and on partner alignment presents a clear risk if competition or pricing rules shift. In addition, governance considerations such as relatively low board independence are relevant. Overall, this is a company where the potential opportunities and the associated risks both warrant closer inspection.

Chugai Pharmaceutical’s rich biologics portfolio and reported profitability numbers are only half the picture; the real question is what the cash flows imply about valuation versus pipeline risk that shows up in the DCF valuation analysis for Chugai Pharmaceutical

Furukawa Electric (TSE:5801)

Overview: Furukawa Electric is a Japan based industrial group that supplies optical fiber and networking gear, energy and power cables, automotive wiring harnesses, and metal products that support global telecoms, data centers, vehicles, and power grids.

Operations: Furukawa Electric generates most of its ¥1,670,558 million revenue from Electrical Electronics at ¥765,067 million and Infrastructure at ¥370,856 million, followed by Functional Products at ¥161,089 million and smaller contributions from Services and Developments and unallocated items.

Market Cap: ¥2.5t

Furukawa Electric may appeal to investors interested in companies linked to data traffic, electrification, and autos, but it can be important to consider whether the current pricing aligns with underlying cash generation. Earnings have grown strongly recently, with a forecast suggesting further growth, and net margins have improved to around 5.5%. However, a sizable one off gain and debt that is not well covered by operating cash flow raise questions about how durable that performance is. The stock has been volatile and carries a relatively high P/E, even as Simply Wall St’s DCF indicates a valuation gap. For investors weighing this mix of growth, funding risk, and index inclusion, the more detailed picture is found in the cash flow statements and the strength of the balance sheet.

Furukawa Electric’s improving margins, recent earnings strength, and premium P/E suggest that the market may be pricing growth while overlooking funding pressure, so it can be worth reading the 3 key rewards and 3 important warning signs (2 are major!)

Murata Manufacturing (TSE:6981)

Overview: Murata Manufacturing is a Japan based electronics company that designs and produces ceramic based components such as capacitors, inductors, communication modules, sensors, batteries, and power products that sit inside smartphones, autos, data centers, industrial equipment, and other connected devices worldwide.

Operations: Murata Manufacturing generates most of its ¥2,062,916 million revenue from Components at ¥1,175,235 million and Devices and Modules at ¥655,981 million, with smaller contributions from Others and corporate eliminations.

Market Cap: ¥15.5t

Murata Manufacturing may interest you if you want exposure to core electronic components tied to smartphones, autos, and data infrastructure, supported by forecasts for strong earnings and revenue growth even after several years of declining earnings and recent margin pressure. The stock trades below Simply Wall St’s estimate of fair value based on future cash flows, yet carries a high P/E and has shown sharp price swings, which underlines how divided the market is on its outlook. In addition, there are capital returns through dividends and a sizable buyback plan, alongside funding and governance questions, making this a business where both the growth story and the risks are important to consider.

Murata Manufacturing’s earnings story and cash flow valuation appear out of sync, with a high P/E and sharp swings hinting at something the market has not fully priced into the analysis report for Murata Manufacturing

The three stocks here are just a starting point. The full Undervalued Stocks Based On Cash Flows screener surfaces 54 more companies where Simply Wall St’s DCF work suggests similarly interesting gaps between price and estimated fair value via the Undervalued Stocks Based On Cash Flows screener. Identify and analyze the specific catalysts and cash flow narratives that matter to you inside Simply Wall St so you can focus on the highest conviction ideas for your watchlist.

Take Control of Your Investment Journey

If Murata Manufacturing or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Others Do

Fresh ideas do not stay quiet for long. The stocks showing early breakout momentum or quietly dropping into value zones are often caught first, before the crowd, so act now.

• Spot potential turnaround stories early by scanning curated 62 high quality undiscovered gems that are still flying under the radar for now, before mainstream attention closes the valuation gap.
• Lock in your own income shortlist by reviewing carefully filtered 44 dividend fortresses while yields, prices, and business fundamentals still line up in your favor.
• Ride structural growth themes by checking focused 35 power grid technology and infrastructure stocks that could benefit if grid investment momentum builds, while valuations still reflect past rather than future demand.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com